SLC5A2 and heart failure: SGLT2 inhibitor use was significantly associated with reduced all-cause mortality (OR 0.27, 95% CI 0.25-0.28), cardiac events (OR 0.49, 95% CI 0.49-0.53), cardiac dysfunction (OR 0.62, 95% CI 0.56-0.69), and heart failure hospitalizations (HFH; OR 0.67, 95% CI 0.61-0.75) compared to non-use.<h4>Conclusion</h4>SGLT2 inhibitors demonstrate robust cardioprotective effects in cancer patients receiving chemotherapy, significantly reducing mortality, HFH, and major cardiac events.